Biotechnology

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

One year after its US launch, Pictor Holdings is gaining traction with a platform that makes complex disease testing fast, cheap, and accessible. But can its unique business model truly scale?

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

A Japanese firm has achieved a breakthrough in manufacturing ultra-smooth capillary tubes, a tiny component set to unlock major advances in medicine and tech.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

With revenues soaring 50%, program manager Primecore is launching into semiconductors and data centers, betting its veteran team can tame the world's most complex projects.